SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc. (OTCBB:AEMD), announced today that it has executed a Cooperative Research and Development Agreement (CRADA) with The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). The focus of the agreement is to explore the therapeutic efficacy of the Aethlon Hemopurifier® against viral hemorrhagic fever (VHF) targets, including, but not limited to Ebola Virus, Marburg Virus, Lassa Virus, and Machupo Virus.
